A Blockbuster Drug Finds a New Target
The numbers from a small but striking trial are hard to ignore. Eight of 11 participants who completed a semaglutide study published in June in the journal Fertility and Sterility lost at least 10% of their body weight. The median weight loss was approximately 42 pounds. The median drop in testosterone was 52%. Six women experienced more frequent periods, and four of them normalized to monthly cycles.
The condition under study is polyendocrine metabolic ovarian syndrome — PMOS — a hormonal disorder affecting 1 in 8 women worldwide. It was renamed earlier this year from polycystic ovary syndrome to shift clinical focus away from ovaries and cysts. There is no known cause and no specific approved treatment, only symptom management through birth control pills, diet and exercise.
The Mechanism Behind the Results
Dr. Melanie Cree, PMOS clinic director at Children's Hospital Colorado and lead researcher on three GLP-1 trials for the condition, explained the underlying biology. Most women with PMOS, regardless of body size, have insulin resistance. Elevated insulin travels directly to the ovaries, spurring excess testosterone production — the driver behind skipped periods, severe acne and abnormal hair growth.
'We are finding them incredibly effective and really exciting for improving symptoms in women with this condition,' Cree said.
Across all three of Cree's studies, women on GLP-1s lost more weight than control groups, and levels of testosterone, blood sugar and insulin declined. The trials examined semaglutide injections, semaglutide pills and exenatide injections respectively. Other global studies have reported similarly positive results, though some researchers caution that the evidence base remains limited given the small sample sizes.
A Patient's Story Puts a Face on the Data
Charlotte Touzalin, an 18-year-old college student from Colorado, began struggling with weight gain, abnormal periods and unwanted facial hair as a young teenager — symptoms that had gone undiagnosed in her mother, Anne Schultz, 43, for decades. Both were eventually diagnosed with PMOS.
Touzalin administered weekly semaglutide injections for 10 months as part of Cree's trial. Abnormal hair growth slowed, her periods normalized and she stopped gaining weight constantly. 'I became a happier version of myself,' she said.
Schultz, who experienced irregular periods, ovarian problems and numerous miscarriages before her own diagnosis, described the moment her daughter finally received answers: 'It was like a godsend.'
Diagnosis for PMOS typically takes years. Symptoms overlap with other conditions, vary widely and are frequently dismissed by physicians.
What the Market Is Watching
The free-enterprise case here is straightforward. GLP-1 drugs — already reshaping the obesity and diabetes treatment landscape — are demonstrating utility across a broader range of metabolic conditions than their original labels suggested. A disorder affecting 1 in 8 women globally, with no approved pharmacological treatment, represents a substantial unmet medical need.
Capital rewards clear rules, and the regulatory pathway for expanded GLP-1 indications will matter enormously. If the evidence base strengthens through larger trials, the commercial opportunity is significant — and so is the potential to reduce the long-term healthcare costs that unmanaged PMOS imposes on patients and, ultimately, on the taxpayer through public insurance programs. The market has already voted on GLP-1 platforms. This data suggests it may not be done voting.
